Hypofractionated radiotherapy for invasive squamous cell carcinoma of the scalp in the elderly : Efficacy and tolerance, preliminary results
Copyright © 2023 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved..
PURPOSE: Skin squamous cells carcinomas (SCC) are frequently tumor, especially in the elderly population. Surgical excision is the standard treatment. But for patients suffering large tumor or/with comorbidity, a conservative approach with irradiation can be proposed. The hypofractionated schedule is used to shorten the overall treatment time with same results and without compromising therapeutic outcomes. The aim of this study is to assess the efficacy and tolerance of hypofractionated radiotherapy for invasive SCC of the scalp in elderly.
PATIENTS AND METHODS: We included patients suffering from SCC of the scalp and treated by hypofractionated radiotherapy at the Institut de cancérologie de Lorraine or centre Émile-Durkeim d'Épinal, from January 2019 to December 2021. Characteristics of patients, size of the lesion and side effects were collected retrospectively. Tumor size at 6 months corresponded to the primary endpoint. Toxicity was collected for the secondary endpoint.
RESULTS: Twelve patients with a median age of 85 years old were included. The mean size was 4,5cm with a bone invasion in 2/3 of cases. Radiotherapy was delivered after surgical excision for half of the patient. The dose delivered was 54Gy in 18 daily fractions size. Six months after irradiation: 6/11 patients had no residual lesion, 2/11 had a partial response with a residual lesion of about 1cm. 3 patients presented local recurrence. One patient died within 6 months of radiotherapy because of another comorbidity. In total, 25% had presented a grade 3 acute radiation dermatitis, no grade 4 toxicity.
CONCLUSION: Short term of moderately hypofractionated schedule radiotherapy was a success with complete or partial response for more than 70% of the patients in squamous cell carcinomas. There is no major side effect.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique - 27(2023), 4 vom: 11. Juni, Seite 290-295 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jacques, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carcinomes épidermoïdes |
|---|
| Anmerkungen: |
Date Completed 05.06.2023 Date Revised 05.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canrad.2023.01.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35681985X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35681985X | ||
| 003 | DE-627 | ||
| 005 | 20231226071256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canrad.2023.01.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM35681985X | ||
| 035 | |a (NLM)37179219 | ||
| 035 | |a (PII)S1278-3218(23)00063-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jacques, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypofractionated radiotherapy for invasive squamous cell carcinoma of the scalp in the elderly |b Efficacy and tolerance, preliminary results |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.06.2023 | ||
| 500 | |a Date Revised 05.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a PURPOSE: Skin squamous cells carcinomas (SCC) are frequently tumor, especially in the elderly population. Surgical excision is the standard treatment. But for patients suffering large tumor or/with comorbidity, a conservative approach with irradiation can be proposed. The hypofractionated schedule is used to shorten the overall treatment time with same results and without compromising therapeutic outcomes. The aim of this study is to assess the efficacy and tolerance of hypofractionated radiotherapy for invasive SCC of the scalp in elderly | ||
| 520 | |a PATIENTS AND METHODS: We included patients suffering from SCC of the scalp and treated by hypofractionated radiotherapy at the Institut de cancérologie de Lorraine or centre Émile-Durkeim d'Épinal, from January 2019 to December 2021. Characteristics of patients, size of the lesion and side effects were collected retrospectively. Tumor size at 6 months corresponded to the primary endpoint. Toxicity was collected for the secondary endpoint | ||
| 520 | |a RESULTS: Twelve patients with a median age of 85 years old were included. The mean size was 4,5cm with a bone invasion in 2/3 of cases. Radiotherapy was delivered after surgical excision for half of the patient. The dose delivered was 54Gy in 18 daily fractions size. Six months after irradiation: 6/11 patients had no residual lesion, 2/11 had a partial response with a residual lesion of about 1cm. 3 patients presented local recurrence. One patient died within 6 months of radiotherapy because of another comorbidity. In total, 25% had presented a grade 3 acute radiation dermatitis, no grade 4 toxicity | ||
| 520 | |a CONCLUSION: Short term of moderately hypofractionated schedule radiotherapy was a success with complete or partial response for more than 70% of the patients in squamous cell carcinomas. There is no major side effect | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Carcinomes épidermoïdes | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a Hypofractionated | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Radiothérapie hypofractionnées | |
| 650 | 4 | |a SCC | |
| 650 | 4 | |a Scalp | |
| 650 | 4 | |a Sujets âgés | |
| 650 | 4 | |a Vertex | |
| 700 | 1 | |a Renard, S |e verfasserin |4 aut | |
| 700 | 1 | |a Demogeot, N |e verfasserin |4 aut | |
| 700 | 1 | |a Faivre, J C |e verfasserin |4 aut | |
| 700 | 1 | |a Peiffert, D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique |d 1998 |g 27(2023), 4 vom: 11. Juni, Seite 290-295 |w (DE-627)NLM092193420 |x 1769-6658 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:4 |g day:11 |g month:06 |g pages:290-295 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canrad.2023.01.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 4 |b 11 |c 06 |h 290-295 | ||